share_log

Avenue Therapeutics | DEFA14A: Others

Avenue Therapeutics | DEFA14A: Others

Avenue Therapeutics | DEFA14A:其他
美股sec公告 ·  05/06 12:47
Moomoo AI 已提取核心信息
Avenue Therapeutics, Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, made under Schedule 14A, is in accordance with Section 14(a) of the Securities Exchange Act of 1934. The materials were submitted by Avenue Therapeutics itself, indicating that they are not preliminary proxy statements nor are they soliciting material under §240.14a-12. Furthermore, the company has confirmed that no filing fee is required for this submission.
Avenue Therapeutics, Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, made under Schedule 14A, is in accordance with Section 14(a) of the Securities Exchange Act of 1934. The materials were submitted by Avenue Therapeutics itself, indicating that they are not preliminary proxy statements nor are they soliciting material under §240.14a-12. Furthermore, the company has confirmed that no filing fee is required for this submission.
作为委托书的一部分,Avenue Therapeutics, Inc.已向美国证券交易委员会(SEC)提交了明确的额外材料。该文件根据附表14A提交,符合1934年《证券交易法》第14(a)条。这些材料是由Avenue Therapeutics自己提交的,表明它们不是初步的委托书,也不是根据第240.14a-12条征集材料。此外,该公司已确认本次提交不需要任何申请费。
作为委托书的一部分,Avenue Therapeutics, Inc.已向美国证券交易委员会(SEC)提交了明确的额外材料。该文件根据附表14A提交,符合1934年《证券交易法》第14(a)条。这些材料是由Avenue Therapeutics自己提交的,表明它们不是初步的委托书,也不是根据第240.14a-12条征集材料。此外,该公司已确认本次提交不需要任何申请费。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息